FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(11IIIt Of Ty	pe Kesponse	8)																
1. Name and Address of Reporting Person * Sonsini Peter W.						2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
					3. Date of Earliest Transaction (Month/Day/Year) 09/07/2018						-	Office	r (give title belo	ow)	Other (specify	below)		
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
MENLO PARK, CA 94025 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)		Date (Month/Day/Year) Ex		Executi any	A. Deemed Execution Date, if ny Month/Day/Year)		Code		4. Securities Acquired (A) of Disposed of (D) (Instr. 3, 4 and 5)		d (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D)	Beneficial Ownership			
							Co	ode	V	Amount		(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Ordinary Shares with a nominal value of 0.001 GBP per share (1)		09/07/2	2018]	P		3,000,00	0		\$ 1.6667 <mark>(2)</mark>	82,978,668 ⁽¹⁾		I	See Note 3		
Ordinary Shares with a nominal value of 0.001 GBP per share (4)		09/07/2018]	P		12,000,0	00		\$ 1.6667 <u>(2)</u>	7 12,000,000 (4)			I	See Note 5	
Reminder:	Report on a s	separate line	e for each		I - Deriv	vative Secu	rities	. Acq	P C tl	ersons whontained in the form dis	no re n thi splay	s for /s a o	m are curren eficially	not requ tly valid		ormation spond unle trol numbe	ss	1474 (9-02)
4 571 0	I.					<u> </u>				ons, conver							2 4 2	44.37
Derivative Conversion Da		Date	3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Deemed Execution Dat any (Month/Day/Y		Date, if	Code	of De Se Ac (A Di of (Ir	umbe	ive les ed ed ed ed	nd Expiration Date Month/Day/Year) Ar Ur Se		Amou Unde Secur (Instr	. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Securit Direct or India	f Benefici Ownersh (Instr. 4) D) ect	
						Code	V (A	A) (Date Exercisable	Expi Date	ration	Title	Amount or Number of Shares				

Reporting Owners

D (O N (Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Sonsini Peter W. 2855 SAND HILL ROAD MENLO PARK, CA 94025		X				

Signatures

/s/ Sasha Keough, attorney-in-fact	09/10/2018

**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates (1) 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
- (2) The price reported in Column 4 of \$1.6667 per ordinary share is a price derived from the price of \$10.00 per ADS, divided by six.
- The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general (3) partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the
- (3) partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest.
- The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates (4) 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
- The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.